Luye Pharma Group Ltd.

As of December 31, 2025, Luye Pharma Group Ltd. carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Luye Pharma Group Ltd.'s next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2025, Luye Pharma Group Ltd. has 3.99B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Luye Pharma Group Ltd. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Luye Pharma Group Ltd.'s stock has declined approximately 47.13% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.25.

As of December 31, 2025, Luye Pharma Group Ltd. holds 912.26M in cash and equivalents against 1.15B in total debt, resulting in a net debt position of 591.01M. Total book value stands at 1.96B, with working capital of 644.71M providing operational flexibility.